Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
2.
Ann Oncol ; 26(7): 1353-62, 2015 Jul.
Article in English | MEDLINE | ID: mdl-25851629

ABSTRACT

BACKGROUND: Lymphopenia is a predictive factor for hematological toxicity, progression and early death in advanced cancers including metastatic breast cancer (MBC). CYT107 is a recombinant interleukin 7 (IL-7) (Cytheris, now Revimmune), well tolerated and able to expand lymphocyte pool in humans. The aims of this study were to determine the optimal schedule to deliver CYT107 and to assess its effect on clinical end points. PATIENT AND METHODS: This placebo-controlled, double blind, phase IIa was conducted in MBC patients with <1500/µl lymphocytes treated with capecitabine. Using a 2-by-2 factorial design, 20 patients were randomly allocated to four arms to receive (i) before chemotherapy: CYT107 or placebo; then (ii) during chemotherapy: CYT107 or placebo. The primary end point was CD4+ count changes before and during chemotherapy. Secondary end points were hematological toxicity, safety, overall response, progression-free survival (PFS) and overall survival (OS). Quantification and functional competence of circulating immune cells were also assessed. RESULTS: When administered before chemotherapy, CYT107 induced a significant increase of CD4+ [+148.1% in CYT107 versus +9.9% in placebo groups, (Wilcoxon, P = 0.002)] and CD8+ T-cell counts, including both naïve and memory subsets. When CYT107 was administered during chemotherapy, the magnitude of CD4+ and CD8+ increase was less important. No modulation of immune cell functional competence was observed. CYT107 was well tolerated with no related ≥grade 3 adverse events except 1 fatal suspected unexpected serious adverse reaction (SUSAR) of uncertain relationship. Of the 12 cases evaluable for response, 6 of 7 patients (86%) receiving CYT107 before chemotherapy achieved a response or stabilization, whereas two of five patients (40%) receiving placebo achieved the same result. No significant difference was observed for PFS or OS. CONCLUSION: In lymphopenic MBC, CYT107 increases CD4+ and other T-cell subset counts without altering their function. A larger clinical trial to demonstrate its impact on clinical outcome is warranted. CLINICALTRIALSGOV IDENTIFIER: NCT01362107.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Breast Neoplasms/drug therapy , Carcinoma, Ductal, Breast/drug therapy , Carcinoma, Lobular/drug therapy , Interleukin-7/therapeutic use , Lymphopenia/drug therapy , Recombinant Proteins/therapeutic use , Adult , Aged , Biomarkers, Tumor/metabolism , Breast Neoplasms/mortality , Breast Neoplasms/pathology , CD4 Lymphocyte Count , Carcinoma, Ductal, Breast/mortality , Carcinoma, Ductal, Breast/secondary , Carcinoma, Lobular/mortality , Carcinoma, Lobular/secondary , Double-Blind Method , Female , Follow-Up Studies , Humans , Immunoenzyme Techniques , Lymphatic Metastasis , Lymphopenia/mortality , Lymphopenia/pathology , Middle Aged , Neoplasm Staging , Prognosis , Receptor, ErbB-2/metabolism , Receptors, Estrogen/metabolism , Receptors, Progesterone/metabolism , Survival Rate
3.
Br J Cancer ; 109(4): 909-14, 2013 Aug 20.
Article in English | MEDLINE | ID: mdl-23922114

ABSTRACT

BACKGROUND: Soft tissue sarcomas (STS) are rare tumours for which treatment options are limited in the advanced setting. Histone deacetylase inhibitors have shown activity in preclinical models of STS. METHODS: We conducted a single-arm, open-label, multicentre phase II study to assess the efficacy and tolerability of panobinostat given orally, 40 mg thrice weekly in patients with advanced pretreated STS. The primary endpoint was the 3-month progression-free rate. RESULTS: Forty-seven STS patients were enrolled between January 2010 and December 2010. Median age was 59 (range 21-79) years, 22 (47%) patients were males. Panobinostat dose was lowered to 20 mg thrice weekly after nine patients were enrolled, based on the recommendation of an independent safety committee. The most common grade 3/4 adverse events were thrombocytopenia, fatigue, lymphopenia and anaemia. Forty-five patients were evaluable for the primary endpoint. Among them, nine patients (20%, 95% CI (10-35%)) were progression-free at 3 months. No partial response was seen, but 17 patients (36%) had stable disease (SD) as their best response. Six patients were progression-free at 6 months. CONCLUSION: Panobinostat was poorly tolerated at 40 mg thrice a week. Efficacy in unselected advanced STS was limited, although some patients had prolonged SD.


Subject(s)
Antineoplastic Agents/therapeutic use , Hydroxamic Acids/therapeutic use , Indoles/therapeutic use , Sarcoma/drug therapy , Adult , Aged , Disease-Free Survival , Female , Humans , Leiomyosarcoma/drug therapy , Leiomyosarcoma/pathology , Liposarcoma/drug therapy , Liposarcoma/pathology , Liposarcoma, Myxoid/drug therapy , Liposarcoma, Myxoid/pathology , Male , Middle Aged , Nerve Sheath Neoplasms/drug therapy , Nerve Sheath Neoplasms/pathology , Panobinostat , Salvage Therapy/methods , Sarcoma/pathology , Sarcoma, Alveolar Soft Part/drug therapy , Sarcoma, Alveolar Soft Part/pathology , Sarcoma, Endometrial Stromal/drug therapy , Sarcoma, Endometrial Stromal/pathology , Sarcoma, Synovial/drug therapy , Sarcoma, Synovial/pathology , Treatment Outcome , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...